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BACKGROUND AND PURPOSE  
Cholesteryl butyrate solid lipid nanoparticles (cholbut SLN) can be a delivery system for the anti-
cancer drug butyrate. We have previously shown that they inhibit adhesion of polymorphonuclear and 
tumor cells to endothelial cells and migration of tumor cells, suggesting that they may act as anti-
inflammatory and antitumor agents. The aim of the research was to evaluate the activity of cholbut 
SLN on tumor cell growth using in vitro and in vivo models.  
EXPERIMENTAL APPROACH 
Cholbut SLN were incubated with four tumor cell lines, and cell growth was analysed by assessing 
viability, clonogenic capacity and cell cycle. The effect on signalling was evaluated by western blot 
analysis of Akt expression. The in vivo anti-tumor activity was assessed using two models of PC-3 cell 
xenografts in SCID/beige mice. 
KEY RESULTS 
Cholbut SLN inhibited tumor cell line viability, clonogenic activity, Akt phosphorylation, and cell cycle 
progression. Mice were injected i.v. with PC3-Luc cells and treated with cholbut SLN. In vivo optical 
imaging and histological analysis showed that no metastases were detected in the lungs of the treated 
mice. Mice were injected s.c. with PC-3 cells and treated with cholbut SLN when the tumor diameter 
reached 2 mm. Analysis of the tumor dimensions showed that treatment with cholbut SLN substantially 
delayed tumor growth.  
CONCLUSION AND IMPLICATIONS 
These results demonstrated that cholbut SLN is effective in inhibiting tumor growth and suggest that 
this effect may partly involve inhibition of AKT phosphorylation, which adds another mechanism to the 
activity of this multifaceted drug.  
 
Key words: Solid lipid nanoparticles, cholesteryl butyrate, clonogenic assay, tumor growth in vivo. 
Abbreviations 
Cholbut, cholesteryl butyrate; SLN, solid lipid nanoparticles; Cholbut SLN, Cholesteryl butyrate solid 
lipid nanoparticles; EPR, enhanced permeability and retention; FCS, fetal calf serum;  HDACI, histone 
deacetylase inhibitor; HUVEC, human umbilical vein endothelial cell; MCT1, monocarboxylate 
transporter 1; Nabut, sodium butyrate; PBS, phosphate buffered saline; P-glycoprotein, Pgp; PMA, 
phorbol 12-myristate 13-acetate; SCFAs, short chain fatty acids; SMCT1, sodium coupled 
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INTRODUCTION 
Cytotoxic anticancer drugs display problems, such as poor specificity, high toxicity, and susceptibility 
to induce drug resistance, which substantially limit their use. Their conventional administration often 
leads to their extensive and indiscriminate binding to body tissues and serum proteins in a highly 
unpredictable manner, and only a small fraction of the drug actually reaches the tumor site (Ho Lun 
Wonget et al., 2007); this reduces their therapeutic efficacy and increases the systemic toxicity. Since 
the early 1990s, a number of solid lipid nanoparticles (SLN) or SLN-based systems have been 
successfully formulated and tested for the delivery of cytotoxic drugs (Ho Lun Wong et al., 2007). 
These are particles of submicron size (50-100 nm) intended to leak out of the blood vessels and 
accumulate within the tumor. In terms of drug stability, drug biodistribution, pharmacokinetics, and 
cancer activity, SLN formulations of anticancer agents have been shown to be superior to the 
corresponding free drug, and they are at least comparable to other drug carrier systems such as 
polymeric systems and liposomes. In many cases, nanoparticles also have the potential to bypass the 
multidrug resistance mechanisms that involve cell-surface pump proteins through their entry into the 
cells via endocytosis (Davis et al., 2008). Moreover, nanocarriers may preferentially concentrate in 
tumors, inflammatory sites, and antigen sampling sites by virtue of the enhanced permeability and 
retention (EPR) effect on the vasculature of these sites. Once biodegradable nanoparticles have 
accumulated at the target site, they can act as local drug depots depending on the make-up of the 
carrier, thus providing a source of continuous supply of encapsulated therapeutic compound(s) at the 
solid tumor site (Singh and Lillard 2009). 
Butyrate has received close attention as a potential chemopreventive agent (Wolloski et al., 2001; 
Delzenne et al., 2003), especially because in vitro exposure of tumor cells to this agent induces 
apoptosis, inhibits proliferation, and promotes differentiation (Kobayashi et al., 2003) in tumor cells 
derived from colorectal, breast, gastric, lung, brain, and pancreas cancers (Brioschi et al., 2008). 
Moreover, Sodium Butyrate (Nabut) has displayed some efficacy as an anti-tumor drug in phase I and 
phase II clinical trials, possibly through its Histone Deacetylase Inhibitor (HDACI) activity (Minucci et 
al., 2006). However, its short half-life limits its clinical use (Pellizzaro et al., 1999), and maintenance 
of therapeutic concentrations requires a continuous parenteral administration. Moreover, compliance is 
further reduced by several adverse events, such as abdominal cramps, nausea, diarrhoea, anaemia, 
headache, and strong odour. 
The warm microemulsion method has been used to prepare Cholesteryl butyrate (cholbut) SLN with an 
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Kataoka, 2009). They had negative zeta potential, high enough in modulus to prevent their aggregation 
and to obtain stable nanoparticle dispersions. They were rapidly internalized and displayed  an 
antitumor effect greater than that of butyrate in several tumor cell lines (Salomone et al., 2001; Serpe et 
al., 2004; Minelli et al., 2012).
.
   
In previous works, we showed that cholbut SLN inhibited adhesion to human umbilical vein 
endothelial cells (HUVEC) and migration of several types, including several cancer cell lines (Dianzani 
et al., 2006, Minelli et al., 2012). The anti-adhesive effect was exerted by acting on both HUVEC and 
the cancer cells. We therefore suggested that cholbut SLN may be used as antitumor agents.  
The aim of the research reported here was to extend these analyses by assessing the anti-proliferative 
potential of cholbut SLN on tumor cell lines and to investigate whether the Akt pathway can be 
involved in determining cholbut SLN effects.  Indeed. activation of Akt  by phosphorylation plays an 
important role in a variety of malignancies such as colon, breast, prostate and non-small cell lung 
cancer, where it is involved in mediating a variety of biological responses, including cell growth, 
proliferation and survival (Roy et al., 2002; Asano et al., 2004).  
The results showed that cholbut SLN strikingly decreased viability and proliferation of the colon cancer 
cell lines HT29, HCT15, and HCT116, and the prostate cancer cell line PC-3, by acting in a 
concentration- and time-dependent manner and with activity higher than that of the free butyrate. These 
effects may involve inhibition of the Akt pathway and cell cycle arrest in the S and G2/M phase. 
Moreover, cholbut SLN inhibited dissemination and growth of cancer cells in vivo, which supports the 
efficacy of cholbut SLN in anti-cancer therapy.  
 
METHODS 
Preparation of cholbut SLN and sodium butyrate solutions  
Cholbut SLN were prepared by warm microemulsion (µE) method reported elsewhere (Minelli et al., 
2012) and described in PATENT WO0030620. Briefly, warm oil-in-water µE was prepared by melting 
cholesterylbutyrate (Asia Talent Chemical, Shenzen China), Epikuron 200 (Cargill, Milan, Italy) at 
85°C as lipid phase, and then adding external water phase containing Sodium Glycocholate (PCA, 
Basaluzzo, Italy). Since melting point of cholesteryl butyrate is 98°C, 2-phenylethanol (Sigma Aldrich, 
Milan, Italy) was used in process to help melting step with goal to add its preservative efficacy in final 
product (final concentration about 0,25% w/V). After stirring, obtained clear µE was dispersed in cold 
water (2/4 °C) with a dispersion ratio µE /water of 1:10.  Cholbut SLN dispersion was then washed by 
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Cut-off 100,000 Da). For in vivo experiments, further concentration of cholbut SLN was performed by 
TFF, up to obtain a concentration more than doubled comparing with original. Finally all aqueous 
dispersions of cholbut SLN, for in vitro or in vivo experiments, were sterilized by filtration at 0.2 µm 
before use, and no loss of cholbut contents was showed by HPLC analysis. 
In Cholbut SLN, the whole lipid matrix itself acts as a prodrug of butyrate. Since the loading efficiency 
of these preparations can’t be properly defined, compared to the usual situation in which a drug is 
incorporated in the SLN carrier, high recovery of the hydrophobic prodrug matrix was taken as the 
reference parameter for quality control. This always detected a minimal concentration reduction during 
4 washing steps, possibly due to adsorption to the membranes, since no cholbut was found in the 
washing water. Moreover, no loss of either cholbut SLN or free butyrate was detected after the 
sterilizing filtration step.  
Characterization of cholbut SLN formulations was performed by Dynamic Light Scattering (DLS, 
Malvern Zetasizer - Nano ZS),  HPLC-UV analysis (Agilent 1260), Field Emission Scanning Electron 
Microscopy (FeSEM–ZEISS, SUPRA 40, GEMINI column, SMARTSEM software) and Laser 
Doppler Micro-electrophoresis (LDME, Malvern Zetasizer-Nano ZS). Gel Permeation 
Chromatography (GPC) analysis have been performed for further studying size distribution, using a 
glass column (1 cm diameter, 25 cm height) filled with Sepharose CL-4B (Sigma Aldrich, Milan, Italy) 
loaded with 1 mL cholbut SLN and eluted with PBS (pH 7.4). 
Sodium butyrate (Nabut) solutions were freshly prepared in sterile water before each experiment, at a 
concentration of 5 M. 
 
Cell culture 
HT29, HCT15 and HCT116 cells from human colon adenocarcinoma were obtained from American 
Type Culture Collection (Manassas, VA), PC-3 from human prostate carcinoma were gifted by Dr. Pili 
(Roswell Park Cancer Institute, Buffalo, USA). Cholbut SLN was produced by Dr. Gasco (Nanovector 
s.r.l. Torino, Italy). The human tumor cell lines were grown in culture dishes as a monolayer in RPMI 
1640 medium plus 10% FCS, 100 U·mL
-1
 penicillin, 100 mg·mL
-1 
streptomycin,  at 37°C in a 5% CO2 
humidified atmosphere.  
PC-3Luc cells were constructed by stably transfecting PC-3 cells with luciferase construct, as 
previously described (Loberg et al., 2006). 
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The effect of cholbut SLN on cell growth and survival was assessed by the MTT assay. Briefly, cells 
were normalized at 800 cells per 100 μl in 96-well plates. After an overnight incubation, the medium 
was replaced with 100 µl of culture medium with from 50 to 300 µM cholbut SLN or NaBut. After 24, 
48 and 72 h of incubation, viable cells were measured, by 2,3-bis[2-methoxy-4-nitro-5sulphophenyl]-
2H-tetrazolium-5carboxanilide (Sigma-Aldrich, Milan, Italy) inner salt reagent, at UV 490 nm, as 
described by the manufacturer’s protocol. In some experiments, cholbut SLN or NaBut from 50 to 300 
µM was refilled every 24 h. The UV readings of controls (i.e., cells that had received no drug) were 
normalized to 100%, and the readings from cholbut SLN-treated cells were expressed as % of controls. 




Cells (800 per well) were seeded into 6-well plates and treated with the compounds. The medium was 
changed after 72 h and cells were cultured for additional 10 days. Subsequently, cells were fixed and 
stained with a solution of 90% crystal violet (Sigma-Aldrich) and 10% methanol. Colonies were then 
photographed and counted with a Gel Doc equipment (Bio-Rad Laboratories, Milan, Italy). 
 
Cell cycle analysis 
PC-3 cells (1.5x10
7
) were seeded and treated with titrated doses (50 to 300 µM) of cholbut SLN. After 
24, 48 and 72 h, adherent and non-adherent cells were collected, washed in 1 x PBS (phosphate 
buffered saline) and fixed in 75% ice cold ethanol and subsequently resuspended in a buffer containing 
0.02 mg·mL
-1
 RNase A (Worthington Biochemical Corporation, Lakewood, NJ), 0.05 mg·mL
-1
 
propidium iodide (Sigma-Aldrich), 0.2% v/v Nonidet P-40 (Sigma-Aldrich), 0.1% w/v sodium citrate 
(Sigma-Aldrich). Samples were acquired with a FACSCalibur cytometer (Becton Dickinson) and 
analyzed with the software FlowJo v8.6.3 (Becton Dickinson). 
In some experiments (n=3), cholbut SLN (50-300 µM) was refilled every 24 h.  
Western blot analysis         
Cells, treated or not with 0.1 mM cholbut SLN for 8-48 h were exposed to 0.01 µM Phorbol 12-
myristate 13-acetate (PMA) (Sigma-Aldrich) for 10 min to stimulate Akt activation. They were then 
lysed in a buffer composed of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% NP40, 
phosphatase and protease inhibitor cocktail (Sigma-Aldrich). Cell lysates were then cleared from 
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a commercial kit (Bio-Rad Laboratories). Proteins (40 µg/lane) were loaded on 10% SDS PAGE gels 
and, after electrophoresis, transferred onto nitrocellulose membranes. These were blocked by 
incubation for 1 h at room temperature with 5% nonfat milk dissolved in TBS Tween 20. The 
membranes were then probed overnight with primary antibodies and, after 3 washes, incubated for 1 h 
with HRP-conjugated secondary antibodies (Bio-Rad Laboratories). Bands were detected by 
chemiluminescence, and densitometric analysis was performed with the Multi-Analyst software 
(version 1.1, Bio-Rad Laboratories).  
 
Tumor growth in vivo 
Female 4–5 week-old SCID/Beige mice (Charles River Laboratories, Milan, Italy) were housed under 
pathogen-free conditions. The mice were manipulated and housed according to protocols approved by 
the Turin University Bioethical Committee and the Italian Ministry of Health.  
In the metastasis experiments, mice were injected in the tail vein with stably expressing firefly 




mouse) and monitored weekly for pulmonary metastases by in 
vivo optical imaging. 
In the tumor growth experiment, mice were injected sub-cutaneously in the left flank with 2x10
6
 PC-3 
cells. Tumor size was weekly quantified in two dimensions using calipers. Tumor volume was 




/2, where D represents the largest cross sectional 
diameter (mm) of the tumor, and d the cross sectional diameter (mm) at right angles to D. 
In each experiment, the mice were treated every 2 days with i.p. injection of 220 mM·Kg
-1
 cholbut 
SLN, or PBS as control. 
 
In vivo optical imaging 
At 0, 7, 14, and 21 days after tumor cell injection, mice (n=9) were injected i.p. with 150 mg·Kg
-1
 
luciferin (PerkinElmer, Waltham, MA) in sterile PBS. They were then placed in the IVIS 200 
(PerkinElmer) induction chamber and subjected to inhalational isoflurane anesthesia (Abbott, Abbott 
Park, IL) at 2.5% with 1 L·min
-1
 flow of oxygen. After 10 min, the mice were placed on the heated 
imaging platform of the IVIS 200 imaging station, with inhalational isoflurane anesthesia during the 
imaging procedure. White light and luciferase activity images were acquired with a 25 s exposure. 
Following imaging, the mice were removed from the imaging stage and allowed to recover from 
anesthesia and returned to their original housing. Images were analyzed with the Living Image software 
(PerkinElmer). The luminescent signal was quantified as the average radiance (p/s/cm
2
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regions of interest (ROIs) drawn in the lungs.  
 
Histopathological analysis 
The lungs were harvested at necropsy and fixed in 10% formalin. The fixed samples were then 
embedded in paraffin and four non-sequential serial sections per animal were obtained. The sections 




Data are shown as mean±SEM. Statistical analyses were performed with GraphPad Prism 3.0 software 




Cholbut SLN was produced by Dr Gasco (Nanovector s.r.l. Turin, Italy). Fetal calf serum (FCS, 
endotoxin tested) was from Hyclone Laboratories (Milan, Italy). Trypsin was from Difco Laboratories 
(Milan, Italy). M199, RPMI 1640, PMA, sodium butyrate and β-actin (A-1978) were purchased from 
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RESULTS  
Cholbut SLN characterization 
Table 1 shows the average diameter (Zave) and polydispersity index (PI) of cholbut SLN, evaluated by 
DLS, and the chemical composition, evaluated by HPLC-UV analysis, at different steps of the 
preparation process. Zeta Potential of cholbut SLN, evaluated by LDME after the final filtration step, 
was - 49.5 mV (Figure 1). FeSEM analysis confirmed the size and spherical morphology of cholbut 
SLN (Figure 2). GPC analysis (data not showed) evidenced the presence of two main populations of 
particles (Zave39% = 183,75 nm, Zave61% = 39,06 nm, Zavemax =  227 nm), which could explain the 
relatively high value of polydispersity index.   
 
Cholbut SLN inhibit tumor cell growth 
Initially, we compared the ability of cholbut SLN and free NaBut to inhibit the growth of HT29, 
HCT116, HCT15 and PC-3 cells. Cells were cultured in the presence and absence of titrated amounts 
(50 µM-0.3 mM) of each compound for 24-48-72 h, and the amount of viable cells was then assessed 
by the MTT assay. In some experiments, each compound was refilled every 24 h. Figure 3 shows the 
inhibition of cell proliferation induced by cholbut SLN and by NaBut. The effect was concentration- 
and time-dependent with some differences between the four cell lines and the two substances. NaBut 
was active only in certain conditions. The most responsive cell line was HCT116, but only at the 
highest compound concentration and after 48-72 h of treatment, showing about 45% of growth 
inhibition at both these times. HCT15, HT29 and PC-3 were only weakly sensitive since they showed a 
respective growth inhibition of <5%, 15%, 20% at 48h, and 15%, 30%, 20% at 72 h. NaBut 
effectiveness increased in the refilling experiments, especially in HCT116 and PC-3, with a maximal 
inhibition of 35-50% obtained at 100 and 300 µM after 72 h for PC-3 and 35-60% for HCT116.  By 
contrast, all cell lines were sensitive to cholbut SLN, especially in the refilling experiment, and the 
maximal inhibition reached approximately 55-80%. To investigate the possibility that cholesteryl esters 
may exert cell toxicity not related to NaBut, we evaluated the effect of similar SLN formulation, having 
cholesteryl palmitate as lipid matrix (50 µM-0.3 mM), on cell growth of the four tumor cell lines   
using the MTT assay. Results showed that cholesteryl palmitate SLN did not exert any effect on cell 
growth even at the highest concentrations (data not shown). These results are in agreement with our 
previous observations showing the ineffectiveness of cholesteryl palmitate SLN in inhibiting adhesion 
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To validate these findings, clonogenic survival assays were performed. Cells were seeded into 6-well 
plates and treated with each compound. The culture medium was changed after 72 h, and cells were 
cultured for an additional 10 days in the absence of the compounds. The results were similar to those 
obtained with the MTT assay (Figure 4). Indeed, only HCT116 and PC-3 were partly sensitive to 
NaBut, whereas all cell lines were sensitive to cholbut SLN, whose maximal inhibition ranged 50-90%. 
The observation that the inhibition detected by the clonogenic assay was substantially higher than that 
detected by the MTT assay suggests that cells which were still viable after the cholbut SLN treatment 
in the MTT assay were severely damaged and unable to proliferate in the clonogenic assay. 
To assess whether inhibition of cell proliferation induced by cholbut SLN affected cell cycle 
progression, we analyzed the cell cycle in PC-3 cells cultured in the presence and the absence of 
titrated amounts (50 - 300 µM) of cholbut SLN for 24-48-72 h (Figure 5a and 5b). Results showed that 
treatment with the highest concentration (300 µM) caused a significant accumulation of cells in the 
G2/M phase, but some effect was detected also at the lower doses. Experiments in which the compound 
was refilled every 24 h and the cell cycle analyzed after 48 and 72 h (Figure 5c and 5d) showed a 
substantial increase of cells in G2/M phase already detectable at the lowest compound dose, whereas 
the highest dose induced accumulation of cells in the SubG1 phase.  
We then evaluated cell death in PC-3 cells refilled with cholbut SLN (50 - 300 µM) for 48-72 h by 
means of Annexin V/Propidium Iodide staining. Figure 6 shows that treatment with 300 µM of cholbut 
SLN caused substantial cell death since only 60% live cells were detected at 48 h, and this value 
decreased to 30% at 72 h. By contrast, the 50 µM and 0.1 mM doses were ineffective in cell death 
induction. 
 
Cholbut SLN modulate Akt signaling 
To investigate the mechanism of cholbut SLN-mediated inhibition of cell proliferation, we evaluated 
Akt phosphorylation, since the Akt signaling pathway is involved in the regulation of cell proliferation, 
apoptosis, adhesion, and migration  (Kwiatkowska et al., 2011; Matsuoka  et al., 2012). To this end, 
HCT15, HCT116, HT29 and PC-3 cells were incubated or not with 100 µM cholbut SLN for 8-48 h 
and then treated with 0.01 µM PMA for 10 min to induce Akt phosphorylation. Western blot analysis 
showed that Akt phosphorylation was induced by PMA in all cell lines (Figure 7), and was inhibited by 
cell treatment with cholbut SLN in a time-dependent manner.  
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To assess the effect of cholbut SLN in vivo, mice were injected i.v. with 1x10
6
 PC-3-Luc cells and 
treated every 2 days with i.p. injection of 220 mM·Kg
-1
 cholbut SLN (n=5) or PBS as control (n=4). 
The dose was chosen according to preliminary experiments that demonstrated  that cholbut SLN did 
not induced any in vivo toxicity in mice upon delivery either p.o. or i.v. (oral LD50 ≥ 1000 mg·kg-1; i.v. 
LD50 ≥ 400 mg·kg-1; Minelli et al., 2011). At time 0, and 7, 14, and 21 days after cell injection, the 
mice were i.p. injected with luciferin and analyzed by in vivo optical imaging to evaluate the tumor cell 
growth in the lungs. Qualitative (8a) and quantitative (Figure 8b) analyses showed that a progressively 
increasing luminescent signal was present in the lungs of 3 out of 4 control mice, while no signal was 
detected in the lungs of the mice treated with cholbut SLN. To refine these data, histological analysis of 
the lungs was performed in the mice sacrificed at day 28. Results showed disseminated tumor foci in 
the lungs of the control mice (Figure 8c, left panel), while no metastases were detected in the lungs of 
the mice treated with cholbut SLN (Figure 8c, right panel).  
To further assess the cholbut SLN effect on the tumor growth in vivo, mice were injected s.c. with PC-3 
cells and treated with either cholbut SLN or PBS starting when the tumor diameter reached 2 mm. 
Analysis of tumor dimensions showed that treatment with cholbut SLN significantly delayed and 
reduced the tumor growth compared to that detected in the control mice (Figure 9). Meanwhile, there 
was no significant difference in body weight between the treated and the control group (data not 
shown), suggesting that the administered dose of cholbut SLN had no significant toxicity to the mice.  
 
DISCUSSION AND CONCLUSION 
Cancer progression is a multi-step process that enables tumor cells to avoid the growth checkpoints of 
the organism, giving rise to a primary tumor mass that may invade the surrounding tissues and even 
disperse far away, leading to metastases. If detected in the early stages, solid cancer is often locally 
circumscribed and can be treated successfully by surgical and radiotherapy removal of the primary 
tumor. The mortality of more than 90% of cancer patients is mostly due to the development of 
metastases (Hayot et al., 2006,). Cell movements through the tissues play a crucial role in cancer 
invasion and dissemination. Therefore, an effective anti-tumor therapy should be effective in inhibiting 
both the growth and invasiveness of tumor cells.  
In an earlier work, we showed that cholbut SLN may have an effect in tumor cell dissemination 
because it inhibited adhesion of tumor cell lines to vascular endothelial cells and their migratory 
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2012). The present work further strengthens findings on the anti-tumor effectiveness of cholbut SLN by 
showing its ability to inhibit cancer cell growth both in vitro and in vivo.  
Our data show that cholbut SLN inhibited tumor cell growth in vitro at higher doses than those 
effective on tumor cell adhesion and migration. The effect was dose- and time-dependent and clearly 
more potent than that displayed by NaBut, which has been found to be ineffective on tumor cell 
adhesion and migration in our previous work. Moreover, NaBut is selectively effective in some tumor 
cell lines, whereas cholbut SLN were active on all cell lines tested. Wilson et al., 2010 demonstrated 
that cancer cell sensitivity to NaBut correlated with its capacity to inhibit HDAC activity. The cholbut 
SLN effect would be independent from HDAC inhibition because our previous work showed that these 
cholbut SLN doses do not inhibit HDAC (Minelli et al., 2012). Moreover, cholbut SLN was similarly 
effective in cell lines whose growth is either sensitive (HCT116) or resistant (HT29) to HDAC 
inhibitors (Wilson et al., 2010).  
Inhibition of cell growth was due to cycle arrest in the G2/M or SubG1 phase and induction of 
significant cell death. 
In our previous work, we showed that cholbut SLN inhibit the ERK and p38 pathways involved in cell 
growth, migration, and adhesion. Now, we extend those findings by showing that it inhibits the Akt 
pathway, too, which is overexpressed in a number of cancers, including colon, pancreatic, ovarian, and 
some steroid hormone-sensitive breast cancers (Roy et al., 2002; Asano et al., 2004). This effect is 
intriguing since the Akt pathway is critical for prostate cancer invasion (Shukla et al.,  2007), promotes 
androgen-independent progression, and is essential for neuroendocrine differentiation of the prostate 
cancer (Li et al., 2007; Wu et al., 2007). Moreover, Akt phosphorylation correlates with cell growth, 
differentiation, and adhesion (Lai et al., 2010), as well as with the invasion grade, vessel infiltration, 
metastasis to lymph nodes, and tumor stage in human colon carcinomas (Itoh et al., 2002; Khaleghpour 
et al., 2004). These data indicate that cholbut SLN have an effect in the signalling machinery of tumor 
cells, but a wider analysis is needed to better depict these effects.  
High concentrations of butyrate (about 2–3 mM) are present in the colon lumen. Since they reach 
pharmacological effectiveness, colon cancer cells can grow only upon development of escape 
mechanisms. Among these, a role seems to be played by the decrease of the intracellular concentration 
of butyrate through downregulation of monocarboxylate transporter 1 (MCT1) and sodium-coupled 
monocarboxylate transporter 1 (SMCT1) (Davis et al., 2008), which are involved in the transport of 
butyrate and other SCFA (short chain fatty acids) anions. Therefore, cholbut SLN may overcome this 
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Indeed, upon treatment with cholbut SLN, substantial uptake of butyrate is already detectable after 15 
min, and it then persists inside the cell for several days (Brioschi et al., 2008; Minelli et al., 2012). 
Development of multidrug resistance in human tumors is one of the main obstacles to the success of 
cancer chemotherapy. This phenomenon is often associated with increased expression of the mdr1 
gene, which encodes P-glycoprotein (Pgp). As an energy-dependent efflux pump, this protein is 
capable of extruding certain drugs from cells, leading to decreased drug concentrations within the cells 
and reduced efficacy of drugs (Stein et al., 1996). The human colon carcinoma cell lines HCT116 and 
HCT15 were selected in this work also because they express the Pgp-mediated type of multidrug 
resistance intrinsically. However, HCT15 displays a greater multidrug resistance than HCT116 
(Iwahshi et al., 1991; Lee et al., 2010), which might explain the higher activity of NaBut on HCT116 
than on HCT15. Therefore, the observation that chobut SLN similarly inhibited HC116 and HCT15 
supports the hypothesis that they escape the transmembrane efflux pumps responsible for drug 
elimination.  
The in vivo data support the in vitro data and show that cholbut SLN have significant antitumor activity 
against PC-3 by inhibiting local tumor growth after  s.c. injection of the cell line. Moreover, it inhibited 
lung metastasis dissemination after i.v. injection of the cell line, which may involve the cholbut SLN 
effect on tumor cell adhesion, migration, and growth. In the light of these results, cholbut SLN might 
be used in neoadjuvant chemotherapy, allowing potentially curative surgery, or after surgical resection 
to inhibit local relapses and metastasis development. 
Inflammation is present in most cancer tissues, including those that have no precancerous lesions, and a 
constant inflammatory state may be necessary to maintain and promote cancer progression to a fully 
malignant phenotype by supporting tumor remodelling, neoangiogenesis, metastasis dissemination, and 
even modulation of the anticancer innate immune response from a protective M1-type response to a 
tumor-promoting M2-type response (Wang et al., 2009). Accordingly, the previously reported anti-
inflammatory activity of cholbut SLN (Dianzani et al., 2006), may add value to the anti-cancer activity 
of this compound since it might help to reset the innate immune response. Since SCID mice display a 
severe defect of the adaptive immune response but maintain a weak innate immune response (Moser et 
al., 1993; Thomsen et al., 2008), this anti-inflammatory effect might have had a role in our in vivo 
experiments.  
In conclusion, cholbut SLN seems to be an effective delivery system for cholbut because it decreases 
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compound’s mechanisms of actions, enabling it to act on multiple key fronts of anti-tumor activity, 
such as tumor cell growth, adhesion, and migration, and recruitment of inflammatory cells. 
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LEGENDS  
Figure 1. Laser Doppler Micro-electrophoresis analysis (LDME). The test was performed on cholbut 
SLN using a Malvern Zetasizer – Nano ZS. Results are showed as total count on Zeta Potential (mV). 
Figure 2. Field Emission Scanning Electron Microscopy (FeSEM) analysis. Image shows the 
morphology of cholbut SLN. White bars represent as scale unite of 200 nm (by cooperation with 
Polytechnik of Turin)  
Figure 3. Inhibition of proliferation following cholbut SLN and NaBut treatment. Cells (800/well) were 
treated with increasing concentrations (50 - 300 µM) of cholbut SLN and NaBut for 24-72 h and the 
result was expressed as the percentage of inhibition versus the control expressed as mean ± SEM (n=5). 
In some experiments, cholbut SLN and NaBut were refilled every 24 h (n=5) without changing the 
culture medium (48h culture: 24+24h; 72 h culture: 24+24+24h). One-way ANOVA and the Dunnett’s 
test revealed statistically significance differences (* p<0.05; ** p<0.01) of treated versus control cells. 
The experiments were performed on HT29 (A), HCT116 (B), HCT15 (C), and PC-3 (D) cells. 
 
Figure 4. Effect of cholbut SLN and NaBut on cell clonogenicity was tested by colony forming assay. 
A: HT29, HCT116, HCT15 and PC-3 cells (500/well) were seeded in 6 well plates and treated with 
each drug at the indicated concentrations for 72 hours. The medium was then changed and cells were 
cultured for additional 10 days and subsequently fixed and stained with crystal violet (n=5). B: 
Quantification of the percentage of inhibition versus the control. Data were analyzed by the one-way 
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Figure 5. Induction of cell cycle arrest by cholbut SLN treatment. A-B: PC-3 cells (1.5x10
5
) were 
treated or not with 50 µM-0.3 mM cholbut SLN for 24-72 h and cell cycle was then assessed by flow 
cytmetry.  C-D: in these experiments, 50 - 300 µM cholbut SLN was refilled every 24 h (48h colture: 
24+24h; 72 h culture: 24+24+24h) without changing the culture medium (A and C: representative cell 
cycle plots; B and D: quantification of cell cycle phases; n=3). 
 
Figure 6. Induction of cell death following treatment with cholbut SLN. PC-3 cells (1.5x10
5
) were 
treated or not with 50 - 300 µM cholbut SLN refilling for 48 (24+24h) -72 h (24+24+24 h) and cell 
death was then assessed by flow cytometry (n=3). One-way ANOVA and the Dunnett’s test revealed 
statistically significance differences (* p<0.05; ** p<0.01) of treated versus control cells. 
 
Figure 7. Effect of cholbut SLN on Akt phosphorylation in HCT15 (A), HCT116 (B), HT29 (C) and PC-
3 (D). Cells were treated with 100 µM cholbut SLN for 8, 24 or 48 h and subsequently incubated with 
fresh media containing (0.01 µM) PMA to induce Akt phosphorylation, which was then evaluated by 
Western blot in the cell lysates; the same blots were probed with anti β-actin antibody as a control. 
Left: Western blot analysis from a representative experiment. Right: Densitometric analysis of Akt 
phosphorylation expressed in arbitrary units from three independent experiments. Data are expressed as 
mean±SEM (n=3) of the percentage of inhibition versus the control. Data were analyzed by the one-
way ANOVA and the Dunnett’s tests (** p<0.01 versus the control). 
 
Figure 8. Effect of cholbut SLN on tumor cell dissemination in vivo. Mice were injected i.v. with 1x10
6
 
PC-3-Luc cells and treated with 220 mM·Kg
-1
 cholbut SLN (n=5) or PBS (control group, n=4). A: At 
time 0, and 7, 14, and 21 days after cell injection, mice were i.p. injected with luciferin and pulmonary 
metastases were macroscopically detectable and documented by in vivo optical imaging. B: The 
luminescent signal was quantified as the average radiance (p/s/cm
2
/sr) measured in regions of interest 
(ROIs) drawn in lungs. C: Non-sequential serial sections were taken from lungs of animals and stained 
with hematoxylin/eosin to highlight pulmonary metastasis. Representative histological analysis of the 
lungs in control mice (left panel) and in treated mice (right panel).  
Statistical analysis was performed with the one-way ANOVA and the Dunnett’s tests (** p<0.01, *** 
p<0.001 versus the control).  
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and treated with either 220 mM·Kg
-1
 cholbut SLN (n=4) or PBS (control group, n=3) starting when the 
tumor diameter reached 2 mm
3
 (size of sc tumors was weekly measured by calipers). Statistical 
analysis was performed with the one-way ANOVA and the Dunnett’s tests (** p<0.01, *** p<0.001 
versus the control).  
Table 1. DLS analysis (Malvern Zetasizer – Nano ZS) Size distribution by intensity and polydispersity 
index . Characterization of cholbut SLN at different steps of the preparation. 
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